$ISRG

GUTHART GARY S sold $4.0M of ISRG (indirect holdings)

GUTHART GARY S sold 10,000 indirectly-held shares of INTUITIVE SURGICAL INC (ISRG) at $400.00 ($4.00M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · GUTHART GARY S
Published Aug 12, 2026, 5:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 10,000 shares at $400/share on 2026-08-11, filed on 2026-08-12, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may briefly react to insider selling headlines, but 10b5-1 context usually limits fundamental implications.

03

What to watch

The filing does not indicate reasons for sale, and the indirect ownership structure plus 10b5-1 timing can make the signal less informative than discretionary sales.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Form 4 shows director GUTHART GARY S sold 10,000 ISRG shares on 2026-08-11 for about $4.0M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The transaction is an open-market sale by a director, explicitly tied to a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider transaction data.

None.

None.

Counterpoint

Even with a 10b5-1 plan, large dollar sales can still be interpreted by some traders as a mild bearish signal, especially if paired with other negative catalysts not mentioned here.

Key entities

  • INTUITIVE SURGICAL INC

    Company whose shares were sold in the reported Form 4 transaction.

  • GUTHART GARY S

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3